The DOI matches its Crossref record; 400 of the 401 references it cites were found in a registry or an index, and 1 are not checked yet; 69 of the 304 sources its claims cite were checked for support.
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Open accessAbstract
In August 2022, these guidelines were reviewed by an expert work group convened by ASH. Review included limited searches for new evidence and discussion of the search results. Following this review, the ASH Committee on Quality agreed to continue monitoring the supporting evidence rather than revise or retire these guidelines at this time. Limited searches and expert review will be repeated annually going forward until these guidelines are revised or retired. Background: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in ∼1 to 2 individuals per 1000 each year, corresponding to ∼300 000 to 600 000 events in the United States annually. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and adult patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 28 recommendations for the initial management of VTE, primary treatment, secondary prevention, and treatment of recurrent VTE events. Conclusions: Strong recommendations include the use of thrombolytic therapy for patients with PE and hemodynamic compromise, use of an international normalized ratio (INR) range of 2.0 to 3.0 over a lower INR range for patients with VTE who use a vitamin K antagonist (VKA) for secondary prevention, and use of indefinite anticoagulation for patients with recurrent unprovoked VTE. Conditional recommendations include the preference for home treatment over hospital-based treatment for uncomplicated DVT and PE at low risk for complications and a preference for direct oral anticoagulants over VKA for primary treatment of VTE.
Verified 2026-10-05 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
These ASH 2020 guidelines provide 28 GRADE-based recommendations for treatment of DVT and PE in patients without cancer, covering initial management, primary treatment, secondary prevention, recurrent events, and additional management issues. Strong recommendations include thrombolysis for PE with hemodynamic compromise, INR 2.0-3.0 over a lower INR range for VKA secondary prevention, and indefinite anticoagulation for recurrent unprovoked VTE.
Key findings
- The panel agreed on 28 recommendations. Strong recommendations include thrombolytic therapy for PE with hemodynamic compromise, INR range 2.0-3.0 over lower INR for VTE patients on a VKA for secondary prevention, and indefinite anticoagulation for recurrent unprovoked VTE. Conditional recommendations include home treatment over hospital treatment for uncomplicated DVT and low-risk PE, and DOACs over VKAs for primary treatment of VTE.
- DOAC vs VKA: major bleeding was reduced with DOACs (RR, 0.63; 95% CI, 0.47-0.84; ARR, 6 fewer per 1000 patients; high-certainty evidence), with no impact on mortality (RR, 0.99; 95% CI, 0.85-1.15) or PE (RR, 0.97; 95% CI, 0.77-1.23), and a non-significant reduction in DVT (RR, 0.80; 95% CI, 0.59-1.09).
- Home vs hospital for DVT: home treatment reduced PE (RR, 0.64; 95% CI, 0.44-0.93; ARR, 25 fewer per 1000 patients) and subsequent DVT (RR, 0.61; 95% CI, 0.42-0.90; ARR, 29 fewer per 1000 patients), with lower major bleeding (RR, 0.67; 95% CI, 0.33-1.36; low-certainty evidence).
- Thrombolysis for PE with hemodynamic compromise may reduce mortality (RR, 0.61; 95% CI, 0.40-0.94; ARR, 58 fewer per 1000 patients; low-certainty evidence), but thrombolytics increased major bleeding (RR, 1.89; 95% CI, 1.46-2.46; ARR, 31 more per 1000 patients; high-certainty evidence) and intracranial bleeding (RR, 3.17; 95% CI, 1.19-8.41; ARR, 7 more per 1000 patients; moderate-certainty evidence).
Methods
- ASH formed a multidisciplinary guideline panel balanced to minimize bias; the McMaster University GRADE Centre supported guideline development, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes, used the GRADE approach and Evidence-to-Decision frameworks, and subjected recommendations to public comment.
- Evidence synthesis included searches for systematic reviews on MEDLINE, Embase, the Cochrane Library, and Epistemonikos from inception to January 2017, updated to January 2019; the panel conducted its own meta-analyses using random-effects Mantel-Haenszel methods, explored heterogeneity with χ² and I², and used RevMan 5.3.
- Outcomes rated critical across questions were mortality, PE, proximal DVT, and major bleeding; PTS was also rated critical for thrombolysis in DVT and compression stockings questions.
Limitations
- The paper states that not all day-to-day challenges in VTE treatment are covered, that new evidence may change recommendations especially those based on low- or very-low-certainty evidence, and that the recommendations do not replace careful consideration of specific clinical circumstances and patients’ values and preferences.
- The paper states and the text makes evident that many recommendations are conditional because of low or very low certainty; evidence limitations include imprecision, risk of bias (e.g., unblinded trials), indirectness, small event numbers, and lack of head-to-head DOAC comparisons.
- The paper states the guidelines were developed primarily for North America, and resource considerations, feasibility, and acceptability may vary by region; cancer, high bleeding risk, renal/hepatic insufficiency, and antiphospholipid syndrome are noted as populations for which some recommendations may not apply or are addressed separately.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
47 Valid · 4 Not valid · 93 Not checked · 207 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All of them suggested that DOACs are costeffective relative to VKA. 100,104-116”
What the sources say
- Not checked — no full text of the sourcecites [100] Amin, 2014, Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients, J Med Econ source
- Supportedcites [104] Bamber, 2015, Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist, Thromb J source
This paper is one of the economic evaluations cited for the collective statement. Its Results report that rivaroxaban was cost-effective for patients with VTE compared with LMWH/VKA, including across the modeled treatment durations; the paper does not need to evaluate every DOAC to support its place in that set. (LLM, conf=0.91)
- Partly supportedcites [105] Jimenez, 2015, Cost-effectiveness of rivaroxaban in the treatment of venous thromboembolism in Spain, Pharmacoeconomics - Spanish Research Articles sourceExperimental — accuracy not yet measured
The Abstract (p. A643) projects savings for the Spanish health system when rivaroxaban replaces LMWH monotherapy in VTE treatment. It does not establish cost-effectiveness relative to VKA, assess other DOACs, or support the claim about all identified evaluations. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [106] Jugrin, 2015, The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK, Thromb Haemost source
- Not checked — no full text of the sourcecites [107] Lanitis, 2016, Cost-effectiveness of apixaban versus other oral anticoagulants for the initial treatment of venous thromboembolism and prevention of recurrence, Clin Ther source
- Partly supportedcites [108] Law, 2016, A pharmacoeconomic study of traditional anticoagulation versus direct oral anticoagulation for the treatment of venous thromboembolism in the emergency department, CJEM sourceExperimental — accuracy not yet measured
The Conclusions (p. 8) say the analysis suggests DOACs are cost-effective for VTE treatment in the ED, specifically for patients suitable for outpatient therapy. But the Abstract (p. 1) limits the cost saving to the hospital perspective and reports higher patient costs; the comparison was with warfarin plus low-molecular-weight heparin, not VKA alone. The unqualified claim is therefore broader than this evaluation supports. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [109] Lefebvre, 2014, Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism, J Med Econ source
- Not checked — no full text of the sourcecites [110] Maervoet, 2015, Cost effectiveness of rivaroxaban versus low molecular weight heparin and vitamin K antagonists for the treatment of deep-vein thrombosis in the Belgian healthcare setting, Eur J Cardiovasc Med doi:10.5083/ejcm.20424884.137
- Supportedcites [111] Preblick, 2015, Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study, Hosp Prac (1995) source
The Conclusion (p. 10) identifies this paper as an economic evaluation finding edoxaban cost-effective relative to warfarin for VTE. The Discussion (p. 9) also reports that other NOAC evaluations found cost-effective alternatives to warfarin and concludes that NOACs are generally cost-effective by that comparison. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [112] Quon, 2016, Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada, J Med Econ source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Most patients with PE continue to be admitted to the hospital for treatment initiation, including a significant proportion of individuals who could be treated at home. 61”
What the sources say
- Supportedcites [61] Peacock, 2019, Reducing the hospital burden associated with the treatment of pulmonary embolism, J Thromb Haemost source
The Introduction reports that 80%–98% of patients diagnosed with PE are admitted to hospital, while guidelines suggest that approximately 30%–55% are at low mortality risk and may be suitable for early discharge and outpatient treatment. This supports both parts of the citing sentence. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
What the sources say
- Not checked — no full text of the sourcecites [86] Agnelli, 2013, AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [87] Agnelli, 2007, ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study, Circulation source
- Not checked — no full text of the sourcecites [88] Bauersachs, 2010, EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [89] Buller, 2008, Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study, J Thromb Haemost source
- Not checked — no full text of the sourcecites [90] Büller, 2013, Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [91] Buller, 2008, Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study, Blood source
- Supportedcites [92] Büller, 2012, EINSTEIN–PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med source
The citation identifies a trial contributing to the citing authors’ DOAC-versus-VKA analysis. The Methods (p. 1) describe a comparison of rivaroxaban with enoxaparin followed by a vitamin K antagonist. The no-interaction finding is presented as the citing authors’ own subgroup-analysis result, not as a finding of this trial. (LLM, conf=0.91)
- Supportedcites [93] Nakamura, 2015, Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study), Circ J source
The Discussion (p. 7) identifies this as a study comparing apixaban with UFH/warfarin, so it supports its inclusion among the cited DOAC-versus-VKA evidence. The sentence says the citing authors conducted the subgroup analysis; it does not attribute the no-interaction finding to this individual trial. (LLM, conf=0.90)
- Supportedcites [94] Piazza, 2016, Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study, Vasc Med source
The Methods (Statistical analysis) describe a trial comparing edoxaban monotherapy with parenteral anticoagulation followed by warfarin, so this paper qualifies as evidence in the cited DOAC-versus-VKA group. The sentence presents the no-interaction finding as the citing authors’ own subgroup analysis, not as a finding of this individual study. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [95] Schulman, 2014, RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Weidentified 11 systematic reviews 119-129 and 19 randomized trials (n 5 1944). 130-148”
What the sources say
- Not checked — no full text of the sourcecites [119] Alesh, 2007, Catheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review, Catheter Cardiovasc Interv source
- Not checked — no full text of the sourcecites [120] Broholm, 2010, Catheter-directed thrombolysis in the treatment of iliofemoral venous thrombosis. A review, Int Angiol
- Not checked — no full text of the sourcecites [121] Casey, 2012, Treatment of acute iliofemoral deep vein thrombosis, J Vasc Surg source
- Not checked — no full text of the sourcecites [122] Du, 2015, Catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis - a meta-analysis, Vasa source
- Not checked — no full text of the sourcecites [123] Goldhaber, 1984, Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis, Am J Med source
- Not checked — no full text of the sourcecites [124] Karthikesalingam, 2011, A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis, Eur J Vasc Endovasc Surg source
- Not checked — no full text of the sourcecites [125] Ng, 1998, Meta-analysis of streptokinase and heparin in deep vein thrombosis, Am J Health Syst Pharm source
- Supportedcites [126] Watson, 2016, Thrombolysis for acute deep vein thrombosis, Cochrane Database Syst Rev source
The citation identifies one of the systematic reviews, not the source for the citing authors’ totals of 11 reviews and 19 trials. The paper describes itself as a systematic review in ‘Why it is important to do this review’ and discusses thrombolysis for proximal DVT in ‘Authors’ conclusions.’ (LLM, conf=0.91)
- Supportedcites [127] Elbasty, 2017, Safety and efficacy of catheter direct thrombolysis in management of acute iliofemoral deep vein thrombosis: a systematic review, Vasc Specialist Int source
The cited work identifies itself as a systematic review and describes its literature search in Materials and Methods. In the citing sentence, references 119–129 identify the 11 systematic reviews; the totals of 11 reviews and 19 trials are the citing authors’ own count, not findings attributed to this individual review. (LLM, conf=0.91)
- Supportedcites [128] Li, 2018, Catheter-directed thrombolysis for patients with acute lower extremity deep vein thrombosis: a meta-analysis, Rev Lat Am Enfermagem source
The citation to this paper falls in the 119–129 range attached to “systematic reviews,” not the 130–148 range attached to randomized trials. The Methods describe a literature search, and the Discussion identifies the work as a meta-analysis of catheter-directed thrombolysis for lower-extremity DVT. It therefore supports its identification as a review; the trial count is not attributed to it. (LLM, conf=0.91)
plainn = 1,944- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
What the sources say
- Not checked — no full text of the sourcecites [86] Agnelli, 2013, AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [87] Agnelli, 2007, ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study, Circulation source
- Not checked — no full text of the sourcecites [88] Bauersachs, 2010, EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [89] Buller, 2008, Botticelli Investigators, Writing Committee. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study, J Thromb Haemost source
- Not checked — no full text of the sourcecites [90] Büller, 2013, Hokusai-VTE Investigators Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med source
- Not checked — no full text of the sourcecites [91] Buller, 2008, Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study, Blood source
- Supportedcites [92] Büller, 2012, EINSTEIN–PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med source
The Methods (p. 1) identify this as a trial comparing the DOAC rivaroxaban with enoxaparin followed by a vitamin K antagonist, making it an appropriate study to cite among those analyzed. The statement about no interaction between agents is the citing authors’ own subgroup-analysis result, not a finding attributed to this individual trial. (LLM, conf=0.88)
- Supportedcites [93] Nakamura, 2015, Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study), Circ J source
The citation identifies a study contributing evidence to the citing authors’ DOAC-versus-VKA subgroup analysis; the no-interaction finding is the citing authors’ own analysis, not a finding attributed to this individual study. The Study Design (p. 2) describes apixaban and UFH/warfarin treatment groups, and Patient Disposition (p. 3) reports 40 subjects randomized to each. (LLM, conf=0.90)
- Supportedcites [94] Piazza, 2016, Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study, Vasc Med source
The citation is attached to the evidence used in the citing authors’ subgroup analysis, not to their own finding of no interaction. The Methods (Study population; Statistical analysis) describe a randomized comparison of edoxaban with heparin bridging to warfarin in patients with symptomatic DVT, so this paper fits the cited body of DOAC-versus-VKA evidence. No page numbers are available in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [95] Schulman, 2014, RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
236 more claims · 33 with their cited sources checked
Create a free account to see all 351 claims and every source verdict.
- Probably not a substantial claim. 52
- It may state two separate claims as one. 66
- The quote only partly states this claim. 7
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Summary of the evidence · p. 31
“Trials included PE patients who were previously receiving aspirin for prevention of CVD and had initiated anticoagulation therapy.”
§ Certainty in the evidence of effects · p. 31
“Third, the included trials were conducted for patients without VTE.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Benefits · p. 11
“RR, 0.99”
§ Benefits · p. 11
“95% CI, 0.85-0.15”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Conclusions and implementation considerations · p. 26
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE”
§ References · p. 45
“318. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Summary of the evidence · p. 26
“We identified 1 RCT 317 to inform this recommendation. This trial included adults with objectively confirmed DVT and/or PE”
§ References · p. 45
“317. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Initial management: up through the first week · p. 8
“## Initial management: up through the first week”
§ Secondary prevention · p. 3
“Initial management (yellow box) spans the first 5 to 21 days following diagnosis of a new VTE”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 2×
“We made judgments regarding risk of bias, precision, consistency, directness, and likelihood of publication bias and categorized the certainty in the evidence into 4 levels ranging from very low to high.(22,23) In addition, we conducted systematic searches to identify evidence related to baseline risks, values, prefer…”
MethodSelf-citationGRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681 · cited 2×
“We made judgments regarding risk of bias, precision, consistency, directness, and likelihood of publication bias and categorized the certainty in the evidence into 4 levels ranging from very low to high.(22,23) In addition, we conducted systematic searches to identify evidence related to baseline risks, values, prefer…”
Method2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Norderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Goldhaber, S. Z., Visani, L., & De Rosa, M. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07534-5 · Cited by 2,870 · cited 1×
“Patients with acute PE who do not have evidence of hemodynamic compromise, defined as a systolic blood pressure ,90 mm Hg or a decrease in systolic blood pressure $40 mm Hg from baseline, but who do have evidence of right ventricular strain by echocardiography or elevated cardiac biomarker levels (eg, elevated troponi…”
Background
Research works printed but not linked: 21
- 2012, J Clin Epidemiol
- 2020, Canadian Agency for Drugs and Technologies in Health. Rivaroxaban (Xarelto): treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.
- Jimenez, 2015, Cost-effectiveness of rivaroxaban in the treatment of venous thromboembolism in Spain, Pharmacoeconomics - Spanish Research Articles, 12, 147
- Jimenez, 2020, Efficacy of thrombolytic therapy in patients with massive pulmonary embolism: systematic review and meta-analysis, Am J Respir Crit Care Med, 201, A3783
- Liu, 2013, The effect of thrombolysis and anticoagulation therapy in patients with sub-massive pulmonary embolism [in Chinese]. Chongqing Med J, 42, 1288
- Ou, 2012, Analysis of the therapeutic effect of urokinase plus sequential anticoagulation for the treatment of sub-massive pulmonary embolism [in Chinese], J Hainan Medical College, 18, 897
- Sun, 2012, Efficacy of urokinase combined with low molecular weight heparin and warfarin for the treatment of sub-massive pulmonary embolism [in Chinese], Strait Pharmaceutical J, 24, 130
- Zhang, 2012, The effectiveness of low-dose rt-PA thrombolysis in 26 elderly patients with acute sub-massive pulmonary embolism [in Chinese], Shandong Yiyao, 52, 69
- Gong, 2005, Thrombolysis for the treatment of lower extremities deep vein thrombosis [in Chinese], J. Chinese Physician, 7, 1101
- Yu, 2009, Using interventional urokinase thrombolysis for the treatment of low extremities deep vein thrombosis [in Chinese], J Southern Medical University, 9, 1930
- Eichinger, 2013, D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model, J Thromb Haemost, 11, 115
- Lazo-Langner, 2013, The use of the REVERSE study clinical prediction rule for risk stratification after initial anticoagulation results in decreased recurrences in patients with idiopathic venous thromboembolism, J Thromb Haemost, 11, 879
- Marcucci, 2013, External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database, J Thromb Haemost, 11, 879
- 2020, Clinical decision rule validation study to predict low recurrent risk in patients with unprovoked venous thromboembolism (REVERSEII). Identifier NCT00967304
- Raskob, 2011, Risk assessment for recurrent venous thromboembolism (VTE) after 6-14 months of anticoagulant treatment, J Thromb Haemost, 9, 857
- Rodger, 2013, The REVERSE I and II studies: impact of using. Men continue and HERDOO2 clinical decision rule to guide anticoagulant therapy in patients with first unprovoked venous thromboembolism, J Thromb Haemost, 11, 114
- Rodger, 2011, Extended follow-up of the multi-center prospective cohort that derived the ‘men continue and HERDOO2‘ clinical decision rule identifying low risk unprovoked patients, J ThrombHaemost, 9, 39
- Tosetto, 2010, Clinical prediction of VTE recurrence in patients with previous unprovoked venous thromboembolism. Results from an individual-level meta-analysis, Pathophysiol Haemost Thromb
- Tosetto, 2009, Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism, J Thromb Haemost
- 2020, Nederlands Trial Register. Cost-effectiveness of tailoring anticoagulant therapy by a VTE recurrence prediction model in patients with venous thrombo-embolism as compared to care-as-usual: The VISTA study. Trial NL2562 (NTR2680)
- Villalta, 1994, Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [abstract], Haemostasis, 24, 158a
Cited by
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Self-citationKhan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Stevens, S. M., Woller, S. C., Baumann Kreuziger, L., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.056 · Cited by 416
Metadata
- Authors
- Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D. Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J. Schünemann, H., Wiercioch, W., Zhang, Y., & Zhang, Y.
- Affiliations
- Duke University (US)
- Pontificia Universidad Católica de Chile (CL)
- University of Insubria (IT)
- University of Florida Health (US)
- Kaiser Permanente (US)
- University of Pennsylvania (US)
- Amsterdam University Medical Centers (NL)
- Harvard University (US)
- VA Northern California Health Care System (US)
- Sechenov University (RU)
- 14May-Thurner Syndrome Resource Network;
- Washington University in St. Louis (US)
- KU Leuven (BE)
- University of Utah (US)
- 18Department of Pediatrics, University of Antioquia, Medellin, Colombia;
- Hospital Alemán (AR)
- McMaster University (CA)
- 19Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada;
- ORCID
- Ortel, Thomas L.
- Neumann, Ignacio
- Ageno, Walter
- Beyth, Rebecca
- Clark, Nathan P.
- Cuker, Adam
- Hutten, Barbara A.
- Jaff, Michael R.
- Manja, Veena
- Schulman, Sam
- Vedantham, Suresh
- Verhamme, Peter
- Witt, Daniel M.
- D. Florez, Ivan
- Izcovich, Ariel
- Nieuwlaat, Robby
- Ross, Stephanie
- J. Schünemann, Holger
- Wiercioch, Wojtek
- Zhang, Yuan
- Zhang, Yuqing
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-10-02
- Volume
- 4
- Issue
- 19
- Pages
- 4693-4738
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7556153
- OpenAlex
- W3090209681
- Cited by
- 1,489
- References
- 392
- Citations by year
- 2026: 216 · 2025: 293 · 2024: 335 · 2023: 268 · 2022: 213 · 2021: 156 · 2020: 5
- FWCI
- 91.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- IrInSubria (University of Insubria) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- venous thromboembolism, deep vein thrombosis, pulmonary embolism, anticoagulation, thrombolysis, vitamin K antagonists, direct oral anticoagulants, secondary prevention, recurrent venous thromboembolism, unprovoked venous thromboembolism, indefinite anticoagulation, home treatment, international normalized ratio
- MeSH terms
- Hematology, Humans, Pulmonary Embolism, United States, Evidence-Based Medicine, Venous Thrombosis, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. https://app.cochat.ai/papers/10.1182/bloodadvances.2020001830
- The paper
- Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., Thurston, C., Vedantham, S., Verhamme, P., Witt, D. M., D. Florez, I., Izcovich, A., Nieuwlaat, R., Ross, S., J. Schünemann, H., . . . Zhang, Y. (2020). American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Blood Advances. https://doi.org/10.1182/bloodadvances.2020001830
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.